DNA or RNA molecules find a variety of applications in the biopharmaceutical industry for genetic testing, medical research, therapeutic development, forensic investigation, and other analytical processes. It is worth highlighting that several research studies are being conducted to evaluate the use of oligonucleotides, especially DNA, as a therapeutic intervention for treatment of various medical conditions. The approval of the first antisense oligonucleotide drug, Fomivirse, in 1998, led to a surge in the demand of DNA-based interventions. In addition to the application of DNA in therapy development, these entities are also being deployed in genetic diagnostics and have already proven their use in identifying patients across a diverse range of diseases including breast cancer, dyslexia, ovarian cancer, Parkinson’s disease and psoriasis. The advances in medical research have led to establishment of several technologies that can sequence, analyze, and edit different forms of DNA. This, coupled to the increasing use of DNA across diverse range of applications, have urged industry experts to actively look for efficient DNA synthesis technologies that not only facilitate parallelized synthesis of DNA but also provide unmatched precision, scalability, and speed.
It is worth noting that several companies have developed proprietary enzymatic DNA synthesis platforms offering distinct advantages (such as the potential to increase length of DNA fragment, greater accessibility and convenience) over conventional DNA synthesis methods. Given the known merits of such technologies, a significant proportion of medical researchers and therapy / diagnostic developers prefer to outsource DNA synthesis operations to third party platforms / service providers who claim to provide the expertise in DNA synthesis and production. Presently, there are over 65 players that offer DNA synthesis technologies / services, and these players are actively undertaking efforts to build / expand their existing capabilities, in order to cater to the growing demand for DNA synthesis. Given the rising need for DNA across a wide range of applications, we are led to believe that the DNA synthesis platforms and services industry is likely to witness noteworthy growth in the foreseen future.
The “DNA Synthesis Technologies and Services Market, Distribution by Method of DNA Synthesis (Chemical Method and Enzymatic Method), Key Applications Areas (Research & Diagnostics and Therapeutic Applications), Company Size (Small, Mid-sized and Large), and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global, 2022-2035” report features report features a detailed study of the current scenario and future potential of the DNA synthesis technologies and service providers. Further, the study underlines an in-depth analysis, highlighting the capabilities of service providers engaged in this domain.
One of the key objectives of the report was to estimate the existing market size and the future growth opportunities in DNA synthesis technologies and services market, over the next decade. Based on multiple parameters, such as number of projects and service-based cost distribution we have developed informed estimates on the evolution of the market for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across methods of DNA synthesis (chemical method and enzymatic method), application areas (research & diagnostics and therapeutic applications), company size (small, mid-sized and large) and key geographical regions (North America, Europe and Asia-Pacific and RoW). To account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, portraying different tracks of the anticipated industry’s growth.
The report also features detailed transcripts of interview(s) held with representatives of renowned organizations that are engaged in the DNA synthesis technologies and services industry.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
It is worth noting that several companies have developed proprietary enzymatic DNA synthesis platforms offering distinct advantages (such as the potential to increase length of DNA fragment, greater accessibility and convenience) over conventional DNA synthesis methods. Given the known merits of such technologies, a significant proportion of medical researchers and therapy / diagnostic developers prefer to outsource DNA synthesis operations to third party platforms / service providers who claim to provide the expertise in DNA synthesis and production. Presently, there are over 65 players that offer DNA synthesis technologies / services, and these players are actively undertaking efforts to build / expand their existing capabilities, in order to cater to the growing demand for DNA synthesis. Given the rising need for DNA across a wide range of applications, we are led to believe that the DNA synthesis platforms and services industry is likely to witness noteworthy growth in the foreseen future.
Scope of the Report
The “DNA Synthesis Technologies and Services Market, Distribution by Method of DNA Synthesis (Chemical Method and Enzymatic Method), Key Applications Areas (Research & Diagnostics and Therapeutic Applications), Company Size (Small, Mid-sized and Large), and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global, 2022-2035” report features report features a detailed study of the current scenario and future potential of the DNA synthesis technologies and service providers. Further, the study underlines an in-depth analysis, highlighting the capabilities of service providers engaged in this domain.
In addition to other elements, the study covers:
- A detailed assessment of the overall landscape of the DNA synthesis technologies and services market, providing information on type of offering, method of DNA synthesis (chemical method and enzymatic method), type of DNA molecule, custom offerings, and application area. Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.
- Elaborate profiles of the key players involved in providing technologies and services in the DNA synthesis domain. Each profile features a brief overview of the company, its financial information, details on its technology / service portfolio, financial information, and recent developments and an informed future outlook.
- A detailed overview of the current market landscape of oligonucleotide manufacturers focused on research and diagnostic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).
- A detailed overview of the current market landscape of oligonucleotide manufacturers focused on therapeutic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).
- An analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2022, covering product development and commercialization agreements, R&D agreements, technology licensing agreements, other licensing agreements, mergers and acquisitions, and other relevant types of deals.
- A review of the funding and investments made in the domain, in the period between 2017 and 2022, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.
- An in-depth analysis of grants that have been awarded to various research institutes for projects related to DNA synthesis technologies and services, in the period between 2017 and 2022, on the basis of important parameters, such as year of grant award, grant amount awarded, administering institute center, support period, type of grant application, grant activity code, emerging focus area, purpose of grant award, type of recent organization, popular NIH department and prominent program officers.
- A detailed review of more than 12,000 peer-reviewed, scientific articles related to research on DNA synthesis technologies, which have been published between 2017 and 2022, including analysis based on parameters, such as year of publication, key focus area, type of article, popular keywords, popular authors, therapeutic area, geography and key journals (in terms of number of articles published in this domain and impact factor of the journal).
- An in-depth analysis of the patents related to DNA synthesis technologies, filed / granted till 2022, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, and type of applicant, and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
One of the key objectives of the report was to estimate the existing market size and the future growth opportunities in DNA synthesis technologies and services market, over the next decade. Based on multiple parameters, such as number of projects and service-based cost distribution we have developed informed estimates on the evolution of the market for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across methods of DNA synthesis (chemical method and enzymatic method), application areas (research & diagnostics and therapeutic applications), company size (small, mid-sized and large) and key geographical regions (North America, Europe and Asia-Pacific and RoW). To account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, portraying different tracks of the anticipated industry’s growth.
The report also features detailed transcripts of interview(s) held with representatives of renowned organizations that are engaged in the DNA synthesis technologies and services industry.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Who are the leading industry players offering DNA synthesis technologies and services?
- What are the recent developments and emerging trends in the DNA synthesis technologies and services domain?
- Which partnership models are commonly adopted by industry stakeholders in the DNA synthesis technologies and services industry?
- Which are the leading funding organizations providing grants in the DNA synthesis industry?
- What is the trend of capital investments in the DNA synthesis technologies and services market?
- What is the focus of various publications related to DNA synthesis technologies and services?
- How has the intellectual property landscape for DNA synthesis technologies and services market evolved over the years?
- Which factors are likely to influence the evolution of the upcoming DNA synthesis technologies and services market?
- How is the current and future opportunity likely to be distributed across key market segments?
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. PREFACE
3. INTRODUCTION
4. MARKET OVERVIEW: DNA SYNTHESIS TECHNOLOGIES AND SERVICES
5. COMPANY PROFILES
6. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
7. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)
8. PARTNERSHIPS AND COLLABORATIONS
9. FUNDING AND INVESTMENT ANALYSIS
10. GRANT ANALYSIS
11. PUBLICATION ANALYSIS
12. PATENT ANALYSIS
13. DNA SYNTHESIS SERVICES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
List Of Figures
List Of Tables
Companies Mentioned
- Ajinomoto Bio-Pharma Services
- Aldevron
- AltaBioscience
- Ansa Biotechnologies
- Arbor Biosciences
- ATUM
- Beijing SBS
- Bio Basic
- Biolegio
- Biomatik
- Bioneer
- Biosearch Technologies
- Bio-Synthesis
- Blue Heron Biotech
- BOC Sciences
- BR Biochem Life Sciences
- Camena Bioscience
- Catalog
- ChemGenes Corporation
- Creative Biogene
- CustomArray
- CyberGene
- Dalton Pharma Services
- DNA Script
- Eton Bioscience (Subsidiary of Codex DNA)
- Eurofins Genomics
- Eurogentec
- Evonetix
- Futuresynthesis
- Gene Universal
- General Biosystems
- Generi Biotech
- Genewiz
- GenScript
- Glen Research
- Helixworks Technologies
- IBA Lifesciences
- Integrated DNA Technologies
- Iridia
- KareBay Biochem
- Kern Systems
- Kilobaser
- LC Sciences
- metabion
- Microsoft
- Microsynth
- Midland Certified Reagent Company
- Molecular Assemblies
- Moligo Technologies
- Nitto Denko Avecia
- Nuclera Nucleics
- Oligomer Biotechnology
- Origene
- ProMab Biotechnologies
- ProteoGenix
- Quintaribio
- Ribbon Biolabs
- SARTOMED
- Sigma-Aldrich (Acquired by Merck)
- Sunomix Biosciences
- Synbio Technologies
- Syngene
- SynHelix
- Synthomics
- TAG Copenhagen
- Thermo Fisher Scientific
- Xcelris Labs
- Yale School of Medicine
- GE Research
- Baseclick
- French Ministry for Armed Forces
- Dynamic Combinatorial Chemistry (DCC)
- Bright Peak Therapeutics
- Trio Pharmaceuticals
- GeneDesign
- BIOfidal
- Transcenta
- Amptec
- Eton Bioscience
- Glen Research Corporation
- CodexisCodexis
- TeselaGen Biotechnology
- Analog Devices
- imec
- LioniX International
- PeproTech
- Patheon
- GSL Biotech
- Twist Bioscience
- Horizon Discovery
- CustomArray
- Blue Heron Biotech
- SynHelix
- Isolere Bio
- Aldevron
- Biotechnolabs
- iGEM
- Integrated DNA Technologies
- GENEWIZ
- Eurofins Genomics
- Kazusa DNA Research Institute
- GeneBay
- Aldevron
- Agilent Technologies
- Illumina Ventures
- Sofinnova Partners
- Kurma Partners
- Casdin Capital
- Danaher Life Sciences
- M Ventures
- Columbia Threadneedle Investments
- Casdin Capital
- Alexandria Venture Investments
- iSelect Fund
- Codexis
- Argonautic Ventures
- Horizons Ventures
- Mubadala Capital
- Humboldt Fund
- National Science Foundation
- Civilization Ventures
- Illumina Ventures
- Merck Ventures
- Idinvest Partners
- Bpifrance
- Bpifrance
- Life Sciences Partners
- M. Ventures
- Kurma Partners and Idinvest Partners
- Bpifrance
- Merck
- Life Sciences Partners
- Bpifrance
- Life Science Partners
- Bpifrance Large Venture Fund
- Alexandria Venture
- Fidelity Management and Research
- Arrowmark Partners
- Farallon Capital
- Moore Strategic Ventures
- National Human Genome Research Institute
- Coatue Management
- Catalio Capital Management
- Fidelity Management & Research Company
- eureKARE
- Irving Investors
- IST Cube
- tecnet equity
- Hadean Ventures
- Lansdowne Partners
- Helicase Venture
- IST cube
- tecnet equity
- iSelect Fund
- Keshif Ventures
- Agilent Technologies
- LYFE Capital
- National Human Genome Research Institute
- SynBio Innovation Accelerator
- LYFE Capital
- DCVC
- Rising Tide
- Providence Investment Company Limited
- Molten Ventures
- Cambridge Consultants
- Innovate UK
- Draper Esprit
- The Morningside Group
- Providence Investment Company
- Cambridge Consultants
- Rising Tide Fund
- Tech Coast Angels
- The Department of Air Force
- Department of Health and Human Services
- TEEC Angel Fund
- TA Associates
- Colibri Ventures
- Vanderbilt University
- Division of Basic Sciences
- Columbia University Health Sciences
- Medical College of Wisconsin
- Eunice Kennedy Shriver National Institute of Child Health & Human Development
- Univ Of North Carolina Chapel Hill
- Weill Medical Coll of Cornell Univ
- University of Minnesota
- University of Iowa
- National Institute on Aging
- National Institute of Environmental Health Sciences
- University of Wisconsin-Madison
- Life Technologies
- Tosoh
- Achillion Pharmaceuticals
- Harvard College
- Broad Inst
Methodology
LOADING...
